Sentinel lymph node assessment in melanoma: current state and future directions.
automation
complete lymph node dissection
melanoma
sentinel lymph node
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
03
07
2023
received:
01
04
2023
accepted:
05
07
2023
medline:
5
10
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
Assessment of sentinel lymph node status is an important step in the evaluation of patients with melanoma for both prognosis and therapeutic management. Pathologists have an important role in this evaluation. The methodologies have varied over time, from the evaluation of dimensions of metastatic burden to determination of the location of the tumour deposits within the lymph node to precise cell counting. However, no single method of sentinel lymph node tumour burden measurement can currently be used as a sole independent predictor of prognosis. The management approach to sentinel lymph node-positive patients has also evolved over time, with a more conservative approach recently recognised for selected cases. This review gives an overview of past and current status in the field with a glimpse into future directions based on prior experiences and clinical trials.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
669-684Informations de copyright
© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 2021; 71; 7-33.
Leong SP, Pissas A, Scarato M et al. The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. Clin. Exp. Metastasis 2022; 39; 139-157.
Montgomery KB, Correya TA, Broman KK. Real-world adherence to nodal surveillance for sentinel lymph node-positive melanoma. Ann. Surg. Oncol. 2022; 29; 5961-5968.
NCCN. NCCN clinical practice guidelines in oncology. Melanoma: cutaneous. Version 2. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2023.
Starz H, Balda BR, Krämer KU, Büchels H, Wang H. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001; 91; 2110-2121.
Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann. Surg. Oncol. 2004; 11(3 Suppl); 162s-168s.
Rossi CR, De Salvo GL, Bonandini E et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann. Surg. Oncol. 2008; 15; 1202-1210.
van der Ploeg AP, van Akkooi AC, Haydu LE et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur. J. Cancer 2014; 50; 111-120.
van der Ploeg IM, Kroon BB, Antonini N, Valdés Olmos RA, Nieweg OE. Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node. Ann. Surg. 2009; 250; 301-304.
Meier A, Satzger I, Völker B, Kapp A, Gutzmer R. Comparison of classification systems in melanoma sentinel lymph nodes-an analysis of 697 patients from a single center. Cancer 2010; 116; 3178-3188.
Dewar DJ, Newell B, Green MA, Topping AP, Powell BW, Cook MG. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J. Clin. Oncol. 2004; 22; 3345-3349.
Murali R, Cochran AJ, Cook MG et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer 2009; 115; 5026-5037.
Han D, van Akkooi ACJ, Straker RJ 3rd et al. Current management of melanoma patients with nodal metastases. Clin. Exp. Metastasis 2022; 39; 181-199.
College of American Pathologists. Protocol for the examination of biopsy specimens from patients with melanoma of the skin. Version: 4.3.1.0. Northfield, IL: CAP, 2022.
Kretschmer L, Mitteldorf C, Hellriegel S et al. The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma. Mod. Pathol. 2021; 34; 1839-1849.
Vuoristo M, Muhonen T, Koljonen V et al. Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients. Acta Oncol. 2021; 60; 803-807.
Loidi-Pascual L, Librero J, Córdoba-Iturriagagoitia A et al. Sentinel node tumor burden in cutaneous melanoma. Survival with competing risk analysis and influence in relapses and non-sentinel node status: retrospective cohort study with long follow-up in a Spanish population. Arch. Dermatol. Res. 2022; 314; 369-378.
Hartsough EM, Miller D, Shanley R, Domingo-Musibay E, Giubellino A. Sentinel lymph node tumour burden using digital cell count estimation predicts outcomes in melanoma. Histopathology 2022; 80; 954-964.
van Akkooi AC, de Wilt JH, Verhoef C et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann. Oncol. 2006; 17; 1578-1585.
Mitra D, Ologun G, Keung EZ et al. Nodal recurrence is a primary driver of early relapse for patients with sentinel lymph node-positive melanoma in the modern therapeutic era. Ann. Surg. Oncol. 2021; 28; 3480-3489.
Egger ME, Bower MR, Czyszczon IA et al. Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma. J. Am. Coll. Surg. 2014; 218; 519-528.
Cochran AJ, Wen DR, Huang RR et al. Sentinel lymph node melanoma metastases: assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Eur. J. Surg. Oncol. 2022; 48; 1280-1287.
Cadili A, Scolyer RA, Brown PT, Dabbs K, Thompson JF. Total sentinel lymph node tumor size predicts nonsentinel node metastasis and survival in patients with melanoma. Ann. Surg. Oncol. 2010; 17; 3015-3020.
Gershenwald JE, Andtbacka RH, Prieto VG et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J. Clin. Oncol. 2008; 26; 4296-4303.
Scolyer RA, Li LX, McCarthy SW et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am. J. Clin. Pathol. 2004; 122; 532-539.
Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod. Pathol. 2004; 17; 747-755.
Vuylsteke RJ, Borgstein PJ, van Leeuwen PA et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann. Surg. Oncol. 2005; 12; 440-448.
Frankel TL, Griffith KA, Lowe L et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann. Surg. Oncol. 2008; 15; 2403-2411.
Bertolli E, Macedo MP, Pinto CA, Damascena AS, Molina AS, Duprat Neto JP. Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients. Melanoma Res. 2016; 26; 42-45.
Satzger I, Völker B, Meier A, Kapp A, Gutzmer R. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann. Surg. Oncol. 2008; 15; 1723-1732.
Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, Sjoegren P, Steiniche T. Automated digital volume measurement of melanoma metastases in sentinel nodes predicts disease recurrence and survival. Histopathology 2011; 59; 433-440.
Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J. Clin. Oncol. 2010; 28; 4441-4449.
Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG. Prediction of nonsentinel lymph node status in melanoma. Ann. Surg. Oncol. 2003; 10; 27-31.
Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann. Surg. Oncol. 2003; 10; 575-581.
Satzger I, Völker B, Al Ghazal M, Meier A, Kapp A, Gutzmer R. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology 2007; 50; 764-772.
Jackson K, Ruffolo L, Kozakiewicz L et al. Picomets: assessing single and few cell metastases in melanoma sentinel lymph node biopsies. Surgery 2021; 170; 857-862.
El Sharouni MA, Scolyer RA, van Gils CH et al. Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. Eur. J. Cancer 2022; 167; 133-141.
El Sharouni MA, Scolyer RA, van Gils CH et al. Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. Eur. J. Cancer 2022; 167; 123-132.
Oude Ophuis CM, van Akkooi AC, Rutkowski P et al. Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. Eur. J. Cancer 2016; 67; 164-173.
Parrett BM, Accortt NA, Li R et al. The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival. Melanoma Res. 2012; 22; 386-391.
Nelson DW, Stern S, Elashoff DE et al. Impact of time between diagnosis and SLNB on outcomes in cutaneous melanoma. J. Am. Coll. Surg. 2017; 225; 302-311.
Mandalà M, Galli F, Patuzzo R et al. Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: a multicentre study of the Italian Melanoma Intergroup (IMI). Eur. J. Cancer 2020; 137; 30-39.
Tejera-Vaquerizo A, Nagore E, Puig S et al. Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. Eur. J. Cancer 2015; 51; 1780-1793.
Fortes C, Mastroeni S, Caggiati A et al. The effect of time to sentinel lymph node biopsy on cutaneous melanoma survival. Am. J. Surg. 2016; 212; 935-940.
Oude Ophuis CM, Verhoef C, Rutkowski P et al. The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - an EORTC Melanoma Group Study. Eur. J. Surg. Oncol. 2016; 42; 1906-1913.
Aivazian K, Ahmed T, El Sharouni MA et al. Histological regression in melanoma: impact on sentinel lymph node status and survival. Mod. Pathol. 2021; 34; 1999-2008.
Burton AL, Gilbert J, Farmer RW et al. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am. Surg. 2011; 77; 1009-1013.
Kaur C, Thomas RJ, Desai N et al. The correlation of regression in primary melanoma with sentinel lymph node status. J. Clin. Pathol. 2008; 61; 297-300.
Letca AF, Ungureanu L, Şenilă SC et al. Regression and sentinel lymph node status in melanoma progression. Med. Sci. Monit. 2018; 24; 1359-1365.
Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Histologic regression in malignant melanoma: an interobserver concordance study. J. Cutan. Pathol. 1993; 20; 126-129.
Guitart J, Lowe L, Piepkorn M et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch. Dermatol. 2002; 138; 603-608.
Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression. Cancer 1999; 85; 1067-1076.
Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990; 17; 389-395.
Tas F, Erturk K. Presence of histological regression as a prognostic factor in cutaneous melanoma patients. Melanoma Res. 2016; 26; 492-496.
Ribero S, Galli F, Osella-Abate S et al. Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. J. Am. Acad. Dermatol. 2019; 80; 99-105.e5.
Ma MW, Medicherla RC, Qian M et al. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod. Pathol. 2012; 25; 1000-1010.
Gualano MR, Osella-Abate S, Scaioli G et al. Prognostic role of histological regression in primary cutaneous melanoma: a systematic review and meta-analysis. Br. J. Dermatol. 2018; 178; 357-362.
White RL Jr, Ayers GD, Stell VH et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann. Surg. Oncol. 2011; 18; 3593-3600.
Kocsis A, Karsko L, Kurgyis Z et al. Is it necessary to perform sentinel lymph node biopsy in thin melanoma? A retrospective single center analysis. Pathol. Oncol. Res. 2020; 26; 1861-1868.
Maurichi A, Miceli R, Eriksson H et al. Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram. J. Clin. Oncol. 2020; 38; 1591-1601.
Karimipour DJ, Lowe L, Su L et al. Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? J. Am. Acad. Dermatol. 2004; 50; 759-764.
Willis BC, Johnson G, Wang J, Cohen C. SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl. Immunohistochem. Mol. Morphol. 2015; 23; 109-112.
Baisden BL, Askin FB, Lange JR, Westra WH. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am. J. Surg. Pathol. 2000; 24; 1140-1146.
Hatta N, Takata M, Takehara K, Ohara K. Polymerase chain reaction and immunohistochemistry frequently detect occult melanoma cells in regional lymph nodes of melanoma patients. J. Clin. Pathol. 1998; 51; 597-601.
Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am. J. Surg. Pathol. 1988; 12; 612-618.
Cochran AJ, Wen DR, Herschman HR. Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int. J. Cancer 1984; 34; 159-163.
Yu LL, Flotte TJ, Tanabe KK et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999; 86; 617-627.
Cook MG, Massi D, Szumera-Ciećkiewicz A et al. An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. Eur. J. Cancer 2019; 114; 1-7.
Davis J, Patil J, Aydin N, Mishra A, Misra S. Capsular nevus versus metastatic malignant melanoma - a diagnostic dilemma. Int. J. Surg. Case Rep. 2016; 29; 20-24.
Zubovits J, Buzney E, Yu L, Duncan LM. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum. Pathol. 2004; 35; 217-223.
Ordóñez NG. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum. Pathol. 2014; 45; 191-205.
Gonzàlez-Farré M, Ronen S, Keiser E, Prieto VG, Aung PP. Three types of nodal melanocytic nevi in sentinel lymph nodes of patients with melanoma: pitfalls, immunohistochemistry, and a review of the literature. Am. J. Dermatopathol. 2020; 42; 739-744.
Müller CSL, Müller SG, Vogt T, Pföhler C. Current concepts of ectopic nodal inclusions with special emphasis on nodal nevi. J. Dtsch. Dermatol. Ges. 2021; 19; 1145-1157.
Biddle DA, Evans HL, Kemp BL et al. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am. J. Surg. Pathol. 2003; 27; 673-681.
See SHC, Finkelman BS, Yeldandi AV. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma. Pathol. Res. Pract. 2020; 216; 153105.
Lezcano C, Pulitzer M, Moy AP, Hollmann TJ, Jungbluth AA, Busam KJ. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am. J. Surg. Pathol. 2020; 44; 503-508.
Zengin HB, Yildiz B, Pukhalskaya T, Smoller BR. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: a monocentric retrospective study. J. Cutan. Pathol. 2023; 50; 247-258.
Szumera-Ciećkiewicz A, Bosisio F, Teterycz P et al. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. Eur. J. Cancer 2020; 137; 175-182.
Jennings C, Kim J. Identification of nodal metastases in melanoma using sox-10. Am. J. Dermatopathol. 2011; 33; 474-482.
Blochin E, Nonaka D. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes. Histopathology 2009; 55; 626-628.
Kakavand H, Vilain RE, Wilmott JS et al. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod. Pathol. 2015; 28; 1535-1544.
Quattrocchi E, Sominidi-Damodaran S, Murphree DH, Meves A. β3 integrin immunohistochemistry as a method to predict sentinel lymph node status in patients with primary cutaneous melanoma. Int. J. Dermatol. 2020; 59; 1241-1248.
Scolyer RA, Gershenwald JE, Thompson JF. Isolated imunohistochemistry-positive cells without morphologic characteristics of melanoma should not result in designation as a positive sentinel lymph node according to the AJCC 8th edition staging system. Am. J. Surg. Pathol. 2019; 43; 1442-1444.
Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma of the skin. In Amin MB, Edge SB, Greene FL et al. eds. AJCC Cancer Staging Manual. 8th ed. Cham: Springer, 2017; 563-585.
Siroy AE, Aung PP, Torres-Cabala CA et al. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. Hum. Pathol. 2017; 59; 48-54.
Merz SF, Jansen P, Ulankiewicz R et al. High-resolution three-dimensional imaging for precise staging in melanoma. Eur. J. Cancer 2021; 159; 182-193.
Bankhead P, Loughrey MB, Fernández JA et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 2017; 7; 16878.
Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American joint committee on cancer staging system. Ann. Surg. Oncol. 2005; 12; 282-288.
Woods JF, De Marchi JA, Lowery AJ, Hill AD. Validation of a nomogram predicting sentinel lymph node status in melanoma in an Irish population. Ir. J. Med. Sci. 2015; 184; 769-773.
Piñero A, Canteras M, Ortiz E, Martínez-Barba E, Parrilla P. Validation of a nomogram to predict the presence of sentinel lymph node metastases in melanoma. Ann. Surg. Oncol. 2008; 15; 2874-2877.
Lo SN, Ma J, Scolyer RA et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia Nomogram. J. Clin. Oncol. 2020; 38; 2719-2727.
El Sharouni MA, Varey AHR, Witkamp AJ et al. Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort. Br. J. Dermatol. 2021; 185; 412-418.
Carter MA, Flaherty ME, Hemington-Gorse MS, Cubitt MJJ. Predicting outcomes from sentinel node biopsy for melanoma in the UK: is the MIA nomogram the answer? J. Plast. Reconstr. Aesthet. Surg. 2022; 75; 1497-1520.
Verver D, Rekkas A, Garbe C et al. The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. Eur. J. Cancer 2020; 134; 9-18.
Rossi CR, Mocellin S, Campana LG et al. Prediction of non-sentinel node status in patients with melanoma and positive sentinel node biopsy: an Italian Melanoma Intergroup (IMI) Study. Ann. Surg. Oncol. 2018; 25; 271-279.
Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J. Clin. Oncol. 2004; 22; 3677-3684.
Bertolli E, de Macedo MP, Calsavara VF, Pinto CAL, Duprat Neto JP. A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy. J. Am. Acad. Dermatol. 2019; 80; 722-726.
MacDonald S, Siever J, Baliski C. Performance of models predicting residual lymph node disease in melanoma patients following sentinel lymph node biopsy. Am. J. Surg. 2020; 219; 750-755.
Morton DL, Cochran AJ, Thompson JF et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann. Surg. 2005; 242(3); 302-311. discussion 311-13.
Morton DL, Thompson JF, Cochran AJ et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med. 2014; 370; 599-609.
Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J. Clin. Oncol. 1999; 17; 976-983.
Faries MB. Melanoma trials that defined surgical management. J. Surg. Oncol. 2022; 125; 34-37.
Faries MB, Thompson JF, Cochran AJ et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 2017; 376; 2211-2222.
Madu MF, Wouters MW, van Akkooi AC. Sentinel node biopsy in melanoma: current controversies addressed. Eur. J. Surg. Oncol. 2017; 43; 517-533.
Leiter U, Stadler R, Mauch C et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016; 17; 757-767.
Leiter U, Stadler R, Mauch C et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J. Clin. Oncol. 2019; 37; 3000-3008.
van Akkooi A. Minimal SN tumor burden (Minitub). Bethesda, MD: ClinicalTrials.gov [Internet]; 2013 [updated July 17, 2018; cited 2022]. Available at: https://clinicaltrials.gov/ct2/show/NCT01942603
EORTC. 1208: MINITUB Registration Study: EORTC Melanoma Group. [Internet]; [updated October 21, 2013; cited 2022]. Available at: https://www.melanomagroup.eu/site/22-database/minitub/26-minitub-registration-study.html.
Esmaeli B. Sentinel lymph node (SLN) biopsy for conjunctival/eyelid melanoma. Bethesda, MD: ClinicalTrials.gov [Internet]; 2006 [updated April 28, 2022; cited 2022]. Available at: https://clinicaltrials.gov/ct2/show/NCT00386906
Pfeiffer ML, Savar A, Esmaeli B. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade? Ophthalmic Plast Reconstr Surg. 2013; 29; 57-62.
Newton Bishop J. Studying tumor tissue samples from patients with melanoma who have undergone sentinel lymph node biopsy. Bethesda, MD: ClinicalTrials.gov [Internet]; 2009 [updated August 12, 2013; cited 2022. Available at: https://clinicaltrials.gov/ct2/show/NCT00004153.
Mitra A, Conway C, Walker C et al. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br. J. Cancer 2010; 103; 1229-1236.
Ipenburg NA, van der Hage JA, Newton-Bishop JA et al. Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations. Melanoma Res. 2020; 30; 630-631.
Reintgen M, Kerivan L, Reintgen E, Swaninathan S, Reintgen D. Breast lymphatic mapping and sentinel lymph node biopsy: state of the art: 2015. Clin. Breast Cancer 2016; 16; 155-165.
Lucci A, McCall LM, Beitsch PD et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J. Clin. Oncol. 2007; 25; 3657-3663.
Giuliano AE, Ballman KV, McCall L et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017; 318; 918-926.
Galimberti V, Cole BF, Viale G et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19; 1385-1393.
Baljer BC, Hill SR, Coughlan D, Vale L, Rose AM. Time for consensus on ‘high-risk’ - sentinel lymph node biopsy for cutaneous squamous cell carcinoma: an international survey of skin cancer specialists and a literature update. J. Plast. Reconstr. Aesthet. Surg. 2023; 76; 62-64.
Costantino A, Canali L, Festa BM, Spriano G, Mercante G, De Virgilio A. Sentinel lymph node biopsy in high-risk cutaneous squamous cell carcinoma of the head and neck: systematic review and meta-analysis. Head Neck 2022; 44; 2288-2300.
Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World J. Surg. Oncol. 2011; 9; 80.
Sims JR, Grotz TE, Pockaj BA et al. Sentinel lymph node biopsy in Merkel cell carcinoma: the Mayo Clinic experience of 150 patients. Surg. Oncol. 2018; 27; 11-17.
Arruda EP, Higgins KM. Role of sentinel lymph node biopsy in the management of merkel cell carcinoma. J. Skin Cancer 2012; 2012; 176173.
College of American Pathologists. Protocol for the examination of specimens from patients with merkel cell carcinoma of the skin version 4.1.0.0. Northfield, IL: CAP, 2021.
Dogan NU, Dogan S, Favero G, Köhler C, Dursun P. The basics of sentinel lymph node biopsy: anatomical and pathophysiological considerations and clinical aspects. J. Oncol. 2019; 2019; 3415630.
Ong ML, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J. Gastrointest. Surg. 2016; 8; 179-192.
Kiss B, Thoeny HC, Studer UE. Current status of lymph node imaging in bladder and prostate cancer. Urology 2016; 96; 1-7.
Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev. Anticancer Ther. 2018; 18; 775-784.
Lino-Silva LS, Castillo-Medina AL, Salcedo-Hernández RA, García-Pérez L. Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary? Melanoma Res. 2017; 27; 116-120.
Stowman AM, Hickman AW, Gru AA, Slingluff CL Jr. Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry. Melanoma Res. 2017; 27; 369-376.
Mitteldorf C, Bertsch HP, Zapf A, Neumann C, Kretschmer L. Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients. Mod. Pathol. 2009; 22; 1622-1627.
Prieto VG. Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion. Arch. Pathol. Lab. Med. 2010; 134; 1764-1769.
Gill P, Howell J, Naugler C, Daoud MSA. Utility of multistep protocols in the analysis of sentinel lymph nodes in cutaneous melanoma: an assessment of 194 cases. Arch. Pathol. Lab. Med. 2019; 143; 1126-1130.
Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin. Diagn. Pathol. 2008; 25; 100-111.
Cochran AJ, Roberts A, Wen DR et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathology 2004; 36; 478-484.
Gietema HA, Vuylsteke RJ, de Jonge IA et al. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry. J. Clin. Pathol. 2004; 57; 618-620.
Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 2004; 100; 1683-1691.
Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am. J. Surg. Pathol. 2005; 29; 305-317.
Gerami P, Cook RW, Wilkinson J et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin. Cancer Res. 2015; 21; 175-183.
Gerami P, Cook RW, Russell MC et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J. Am. Acad. Dermatol. 2015; 72; 780-5.e3.
Hsueh EC, DeBloom JR, Lee JH et al. Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. JCO Precis Oncol. 2021; 5; PO.20.00119.
Whitman ED, Koshenkov VP, Gastman BR et al. Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. JCO Precis Oncol. 2021; 5; PO.21.00162.
Dillon LD, McPhee M, Davidson RS et al. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. Curr. Med. Res. Opin. 2022; 38; 1267-1274.
Podlipnik S, Boada A, López-Estebaranz JL et al. Using a 31-gene expression profile test to stratify patients with stage I-II cutaneous melanoma according to recurrence risk: update to a prospective, multicenter study. Cancers (Basel) 2022; 14; 1060.
Podlipnik S, Carrera C, Boada A et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. J. Eur. Acad. Dermatol. Venereol. 2019; 33; 857-862.
Zager JS, Gastman BR, Leachman S et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 2018; 18; 130.
Berger AC, Davidson RS, Poitras JK et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr. Med. Res. Opin. 2016; 32; 1599-1604.
Hyams DM, Covington KR, Johnson CE, Plasseraud KM, Cook RW. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations. Future Oncol. 2021; 17; 517-527.
Hao H, Xiao D, Pan J et al. Sentinel lymph node genes to predict prognosis in node-positive melanoma patients. Ann. Surg. Oncol. 2017; 24; 108-116.